Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

  • Fourth M&A transaction highlights portfolio strength

    Novartis has announced yesterday the acquisition of our portfolio company Avidity Biosciences, a pioneer in RNA-based therapeutics for neuromuscular diseases, for approximately USD 12 billion in cash (USD 72 per share).
  • Portfolio outperformance amid early signs of sector recovery

    After a volatile first half, BB Biotech delivered a strong third quarter. Our share price and NAV outpaced the Nasdaq Biotechnology Index (NBI), while a sequence of clinical, regulatory, and M&A milestones reinforced the momentum building across the biotechnology sector.
Excellence in 
Biotech Investments
THE ACCESS TO FAST GROWING BIOTECHNOLOGY COMPANIES
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than 30 years of experience. The shares of BB Biotech are listed on the SIX Swiss Exchange and the Frankfurt Stock Exchange. Its investments are focused on listed companies that are developing and commercializing novel drugs that offer sound value for the healthcare system.

Insights

Corporate News

  • Media Releases

    BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery

  • Media Releases

    BB Biotech to be included in the SPI ESG Index

  • Media Releases

    BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF

  • ad hoc Releases

    BB Biotech AG publishes its interim report

More News
  • Portfolio & Strategy

    Portfolio & Strategy

    Expert Portfolio

    BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential. 

  • Insights

    Top Know-How

    A team of proven biotech specialists at Bellevue Asset Management AG with a successful track record takes care of investments in the most attractive biotech companies. In this section you will get a comprehensive insight into the biotech sector and relevant investment topics.

  • ESG

    Sustainability

    Each investment is systematically reviewed for sustainability risks and breaches of elementary human rights. Bellevue Asset Management AG is a signatory of UN Principles for Responsible Investment.

  • Investment strategy

    Investment strategy

    Active Management with High Conviction

    Besides profitable large cap companies, BB Biotech is building up its investments in promising small and mid cap companies. The team of investment experts is concentrating not only on established target areas such as oncology, orphan diseases and neurological indications, but also on the technologies of tomorrow that could lead to novel treatment methods with attractive therapeutic profiles and substantial economic rewards.